Syncom Formulations Quarterly Results for Trading Insights
SYNCOMF • Latest quarterly financial performance to support trade journaling in Tickjournal
Latest Quarter Net Profit
₹17 Cr
QSept 2025
Syncom Formulations Quarterly Results Key Highlights
- Revenue of ₹127 Cr in Sept 2025 (-18.6% vs Mar 2025, +18.7% vs Sept 2024)
- Net Profit of ₹17 Cr in Sept 2025 (-5.6% vs Mar 2025, +54.5% vs Sept 2024)
- EBITDA of ₹24 Cr in Sept 2025 (-4.0% vs Mar 2025)
- Operating Margin of 15.0% in Sept 2025 (+3.0pp vs Mar 2025)
- Earnings Per Share of ₹0.18 in Sept 2025 (+12.5% vs Mar 2025)
Syncom Formulations Quarterly Results Analysis
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Sept 2024 | Mar 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 127 | 156 | 123 | 107 | 78 | -18.6% | 18.7% |
| Net Profit (₹ Cr) | 17 | 18 | 16 | 11 | 7 | - | - |
| EBITDA (₹ Cr) | 24 | 25 | 22 | 16 | 13 | - | - |
| EPS (₹) | 0.18 | 0.16 | 0.21 | 0.16 | 0.10 | - | - |
| Operating Margin (%) | 15.0% | 12.0% | 14.0% | 12.0% | 13.0% | - | - |
Syncom Formulations Share Price Trend Around Quarterly Results
Visualize Syncom Formulations's 1-year price movement across quarterly results — ideal for logging trades in Syncom Formulations share price
chart using Tickjournal. All values in ₹.
Related Pages for Syncom Formulations
Additional stock information and data for SYNCOMF
Revenue Trend (₹ Cr)
Sept 2024
107
Jun 2025
123
Mar 2025
156
Sept 2025
127
Net Profit Trend (₹ Cr)
Sept 2024
11
Jun 2025
16
Mar 2025
18
Sept 2025
17
Operating Margin Trend (%)
Sept 2024
12.0%
Jun 2025
14.0%
Mar 2025
12.0%
Sept 2025
15.0%
Sector Competitors - Quarterly Performance Comparison
Comparing Syncom Formulations quarterly results with other companies in Healthcare sector
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹417,052.40 Cr | 1729.9 | 14,875 | 3,125 | +10.8% | - | 21.0% | 133.1 |
|
Divis Laboratories
Sept 2025 |
₹176,337.50 Cr | 6616.5 | 2,860 | 689 | +7.1% | - | 24.1% | 254.8 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹136,522.12 Cr | 3963.4 | 3,219 | 591 | +11.3% | - | 18.4% | 226.0 |
|
Cipla
Sept 2025 |
₹118,572.82 Cr | 1465.7 | 7,716 | 1,353 | +12.0% | - | 17.5% | 87.6 |
|
Dr Reddys Laborator…
Sept 2025 |
₹100,998.62 Cr | 1210.1 | 9,135 | 1,337 | +1.1% | - | 14.6% | 74.8 |
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores
All amounts in ₹ Crores